Pure Bioscience, Inc.
PURE· OTC
PUREPure Bioscience, Inc.
Filed Dec 16, 2024 · 10-Q · 46 days after period end · 0001493152-24-050227
| Metric | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 |
|---|---|---|---|---|
| Revenue | $556.00K | $722.00K | $471.00K | $501.00K |
| Net Income | -$689.00K | -$735.00K | -$993.00K | -$796.00K |
| EPS Diluted | -$0.01 | -$0.01 | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
ended Oct 31, 2024 · filed Dec 16, 2024 · 46 d after period end
